Physician profile
Benjamin Farthing
NPI 1194253898
$7,728.21
in general payments reported to CMS, 2019-2025
26 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $76.95 · 2022: $1,514 · 2023: $2,106 · 2024: $2,498 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,506 · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,506.32 |
| Education | $481.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.69 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,031.49 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $824.75 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $660.13 | 2021-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $587.67 | 2022-2025 | |
| Genzyme Corporation | $579.57 | 2022-2025 | |
| Lilly USA, LLC | $445.62 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $360.08 | 2021-2024 | Opzelura |
| Amgen INC. | $273.21 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $249.14 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $236.21 | 2022-2025 | Bimzelx |
| Leo Pharma INC. | $215.90 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.01 | 2023-2025 | Spevigo |
| Pfizer INC. | $151.30 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $124.17 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $88.59 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $85.99 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $82.69 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $47.53 | 2022 | |
| Biofrontera INC. | $40.16 | 2022 | |
| Merz North America, INC. | $36.73 | 2023-2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.79 | 2025 | Cabtreo, Jublia, Siliq |
| Organon LLC | $19.75 | 2024 | |
| Verrica Pharmaceuticals INC. | $17.20 | 2025 | Ycanth |
| Lnhc, INC | $15.14 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $14.70 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Farthing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.